EBITDA surged 44.1 per cent on a YoY basis to Rs 61.67 crore in Q4FY22. Profit after tax jumped a whopping 177 per cent YoY to Rs 25.12 crore in Q4FY22.   

This price action took a shape of a cup pattern. It’s a stage 2b cup pattern, which has a length of about 60-day and a depth of nearly 15 per cent.   

The stock is up by 18.72 per cent on a YTD basis, however, in the last one month, it has managed to eke out gains of 1.37 per cent.

The stock of HFCL has zoomed over 3 per cent on Friday.

However, as the saying goes, ‘every bad day has an end’, the same is turning true for this stock since it jumped more than 10 per cent on a day when the markets are trading in red!

For the market, every adversity is an opportunity and thus, this current geopolitical tension between Russia and Ukraine is also an opportunity in disguise for some.

The stock is likely to remain in the limelight on Wednesday as after the closing bell today, it revealed

It seems that the month of February belongs to Adani! Just a week ago, it was Gautam Adani, who was in the news for surpassing Mukesh Ambani as Asia’s richest person.

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, has announced a strategic tie-up with Mylab Discovery Solutions, India’s leading diagnostic solutions provider. With this association, Shilpa Medicare expects to venture into the vaccine and therapeutics segment

HFCL has announced the signing of a distribution agreement with Ingram Micro India Private Limited (Ingram Micro), which has a distribution network having a far-reaching presence in India and SAARC countries.